GCG and neonatal diabetes mellitus: We hypothesized that low-dose sulphonylureas may work to increase incretin action with only minimal activation of the triggering pathway and, similar to the mechanism for glucose responsiveness in KATP-neonatal diabetes mellitus treated with sulphonylurea, conjectured that this would be due to a partial closure of KATP channels resulting in a rise in beta-cell membrane potential to a level where the incretin pathway may act.